新光药业(300519) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥100,545,259.30, representing an increase of 8.94% compared to ¥92,296,717.31 in the same period last year[5] - Net profit attributable to shareholders decreased by 25.01% to ¥22,830,341.36 from ¥30,445,257.47 year-on-year[5] - Total operating revenue for Q1 2024 reached ¥100,545,259.30, an increase of 8.6% compared to ¥92,296,717.31 in the same period last year[22] - Net profit for Q1 2024 was ¥22,830,341.36, a decrease of 25.1% from ¥30,445,257.47 in Q1 2023[24] - The total comprehensive income for Q1 2024 was ¥22,423,099.18, down from ¥30,579,174.49 in Q1 2023[24] Cash Flow - The net cash flow from operating activities increased by 38.69% to ¥38,871,503.24, up from ¥28,027,614.00 in the previous year[5] - Cash flow from operating activities was ¥104,202,561.78, compared to ¥107,173,830.98 in the previous period[26] - The net cash flow from operating activities for Q1 2024 was CNY 38,871,503.24, an increase of 38.5% compared to CNY 28,027,614.00 in Q1 2023[27] - The net increase in cash and cash equivalents was ¥51,898,027.02, a significant rise of 2628.88% from ¥1,901,807.18 in the same period last year[12] - The ending balance of cash and cash equivalents as of the end of Q1 2024 was CNY 595,843,819.92, down from CNY 623,931,587.44 at the end of Q1 2023[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥944,717,593.83, a 1.54% increase from ¥930,405,790.36 at the end of the previous year[5] - The total liability of the company was ¥78,173,726.46, a decrease from ¥86,285,022.17 year-on-year[23] - The total assets of the company amount to ¥944.72 million, compared to ¥930.41 million at the beginning of the period[19] - The company's inventory decreased to ¥50.34 million from ¥71.42 million, reflecting a reduction of approximately 29.5%[19] - The total liabilities include accounts payable of ¥60.82 million, down from ¥63.88 million[19] Shareholder Information - The total number of common shareholders at the end of the reporting period is 16,742[13] - The largest shareholder, Wang Yuejun, holds 38.25% of the shares, totaling 61,200,000 shares[13] - The total number of shares held by the top ten shareholders is significant, with the top two shareholders holding a combined 55.89%[13] - The company has no preferred shareholders or related party transactions among the top shareholders[14][15] - The company has not reported any changes in the number of restricted shares during the period[16] Operating Costs and Expenses - The company experienced a 39.32% increase in operating costs, amounting to ¥62,812,898.25, primarily due to rising raw material prices[10] - Total operating costs amounted to ¥76,153,559.49, up 31.4% from ¥57,913,730.09 in Q1 2023[23] - Research and development expenses for Q1 2024 were ¥3,945,710.79, an increase from ¥3,581,334.49 in Q1 2023[23] - The cash paid for purchasing goods and services was CNY 34,469,387.44, which is an increase from CNY 32,692,801.45 in the same quarter last year[27] - The cash paid for taxes in Q1 2024 was CNY 13,214,297.95, a decrease of 48.9% compared to CNY 25,879,261.11 in Q1 2023[27] Investment Income - Investment income increased by 109.15% to ¥1,095,815.46, compared to ¥523,933.82 in the previous year[10] - The company recorded a financial income of ¥1,892,311.55, up from ¥1,291,891.86 in the same period last year[23] - Cash inflow from investment activities totaled CNY 106,261,564.38, up from CNY 95,575,369.86 in the same period last year, representing an increase of 11.7%[27] - The net cash flow from investment activities was CNY 13,026,523.78, a significant recovery from a negative cash flow of CNY -26,125,806.82 in Q1 2023[27] - The total cash outflow from investment activities was CNY 93,235,040.60, a decrease of 23.4% from CNY 121,701,176.68 in the previous year[27] Company Strategy - The company is focused on maintaining a stable financial position while exploring potential market expansions and new product developments[14]